Takeda Sees Strong Fundamentals Despite Post-Shire Loss Outlook
Post-Shire Takeda expects losses in its first annual forecast for the combined business, plus "significant headwinds" from expected Velcade erosion. But underlying new and legacy Takeda business is seen remaining strong.
You may also be interested in...
US Product Launches To Plan For In 2020
A sizeable group of key late-stage products have the potential to reach the US market in 2020, according to a recent report from Informa’s Biomedtracker. Pharmaceutical and biotech executives will have to be on their A-game to integrate the new wave of products into patient-centric and market access-friendly commercial strategies.
Takeda Offloads Xiidra As Expected, For $3.4bn Upfront To Novartis
As widely anticipated, Takeda has reached an agreement to divest an ex-Shire ophthalmology drug, as it streamlines the combined post-acquisition business to focus on core therapeutic pillars.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: Leqembi bodes well for Biogen; AbbVie predicts US Humira erosion; Sanofi’s R&D chief moves on; Roche’s ophthalmology plans; and Scrip Asks what 2023 holds for AI in pharma.